Multiple risk factor intervention reduces carotid atherosclerosis in patients with type 2 diabetes

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Tripolt, Norbert J ^a   Narath, Sophie H ^b   Eder, Michaela ^a   Pieber, Thomas R ^a   Wascher, Thomas C ^c   Sourij, Harald ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b JOANNEUM RESEARCH   (Austria)

^c HANUSCH HOSPITAL   (Austria)

Author keywords

Cardiovascular surrogate measurements; Carotid atherosclerosis; Carotid intima media thickness; Intensified risk factor intervention; Type 2 diabetes

Indexed keywords

6 N,N' DIMETHYLARGININE; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE MARKER; ENDOTHELIAL PROGENITOR CELL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PARAMETERS; PRACTICE GUIDELINE; PROCAM SCORE; PROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

AGED; CARDIOVASCULAR AGENTS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84901932190     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-95     Document Type: Article

References (35)

1. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J, Emerging Risk Factors C Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364(9):829-841. Emerging Risk Factors C.
2. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358(6):580-591. 10.1056/NEJMoa0706245, 18256393.
3. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J, Emerging Risk Factors C Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302(4):412-423. 3272390, 19622820, Emerging Risk Factors C.
4. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, Woo KS. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European stroke conferences, mannheim, Germany, 2004, brussels, belgium, 2006, and hamburg, Germany, 2011. Cerebrovasc Dis (Basel, Switzerland) 2012, 34(4):290-296.
5. Baldassarre D, Veglia F, Hamsten A, Humphries SE, Rauramaa R, de Faire U, Smit AJ, Giral P, Kurl S, Mannarino E, Grossi E, Paoletti R, Tremoli E, on behalf of the ISG Progression of carotid intima-media thickness as predictor of vascular events: results from the IMPROVE study. Arterioscler Thromb Vasc Biol 2013, 33(9):2273-2279. 10.1161/ATVBAHA.113.301844, 23825364, on behalf of the ISG.
6. Crouse JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML, Group MS. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297(12):1344-1353. 10.1001/jama.297.12.1344, 17384434.
7. Makris GC, Lavida A, Nicolaides AN, Geroulakos G. The effect of statins on carotid plaque morphology: a LDL-associated action or one more pleiotropic effect of statins?. Atherosclerosis 2010, 213(1):8-20. 10.1016/j.atherosclerosis.2010.04.032, 20494361.
8. Marfella R, Siniscalchi M, Nappo F, Gualdiero P, Esposito K, Sasso FC, Cacciapuoti F, Di Filippo C, Rossi F, D'Amico M, Giugliano D. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 2005, 18(3):308-318. 10.1016/j.amjhyper.2004.09.013, 15797646.
9. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010, 40(1):35-53. 10.1111/j.1365-2362.2009.02234.x, 20055895.
10. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. http://www.idf.org/webdata/docs/WHO_IDF_definition_diagnosis_of_diabetes.pdf.
11. Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004, 44(11):2137-2141. 10.1016/j.jacc.2004.08.062, 15582310.
12. Reinhard H, Jacobsen PK, Lajer M, Pedersen N, Billestrup N, Mandrup-Poulsen T, Parving HH, Rossing P. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. Diabetologia 2010, 53(10):2129-2133. 10.1007/s00125-010-1843-4, 20607514.
13. Meinitzer A, Puchinger M, Winklhofer-Roob BM, Rock E, Ribalta J, Roob JM, Sundl I, Halwachs-Baumann G, Marz W. Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method. Clinica chimica acta; Int J Clin Chem 2007, 384(1-2):141-148.
14. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002, 105(3):310-315. 10.1161/hc0302.102575, 11804985.
15. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study G The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (London, England: 1979) 2001, 101(6):671-679. United Kingdom Prospective Diabetes Study G.
16. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348(5):383-393. 10.1056/NEJMoa021778, 12556541.
17. Vaccaro O, Franzini L, Miccoli R, Cavalot F, Ardigo D, Boemi M, De Feo P, Reboldi G, Rivellese AA, Trovati M, Zavaroni I, Group MIS Feasibility and effectiveness in clinical practice of a multifactorial intervention for the reduction of cardiovascular risk in patients with type 2 diabetes: the 2-year interim analysis of the MIND.IT study: a cluster randomized trial. Diabetes Care 2013, 36(9):2566-2572. 10.2337/dc12-1781, 23863908, Group MIS.
18. Nabavi V, Ahmadi N, Bhatia HS, Flores F, Ebrahimi R, Karlsberg RP, Budoff MJ. Increased carotid wall thickness measured by computed tomography is associated with the presence and severity of coronary artery calcium. Atherosclerosis 2011, 215(1):103-109. 10.1016/j.atherosclerosis.2010.11.034, 21196006.
19. Lorenz MW, von Kegler S, Steinmetz H, Markus HS, Sitzer M. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the carotid atherosclerosis progression study (CAPS). Stroke J Cerebr Circ 2006, 37(1):87-92.
20. Lonn EM, Bosch J, Diaz R, Lopez-Jaramillo P, Ramachandran A, Hancu N, Hanefeld M, Krum H, Ryden L, Smith S, McQueen MJ, Dyal L, Yusuf S, Gerstein HC, Grace, Investigators O Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care 2013, 36(9):2466-2474. 10.2337/dc12-2129, 23564916, Grace, Investigators O.
21. Bots ML, Evans GW, Riley WA, Grobbee DE. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke 2003, 34(12):2985-2994. 10.1161/01.STR.0000102044.27905.B5, 14615619.
22. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, Fullert SD, Sachara C, Pfutzner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005, 111(19):2525-2531. 10.1161/01.CIR.0000165072.01672.21, 15883215.
23. Crouse JR, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995, 75(7):455-459. 10.1016/S0002-9149(99)80580-3, 7863988.
24. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circ 2000, 102(13):1503-1510.
25. Beishuizen ED, Tamsma JT, Jukema JW, van de Ree MA, van der Vijver JC, Meinders AE, Huisman MV. The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2005, 28(7):1668-1674. 10.2337/diacare.28.7.1668, 15983318.
26. Perl S, Schmolzer I, Sourij H, Pressl H, Eder M, Zweiker R, Wascher TC. Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance. Int J Cardiol 2010, 139(3):289-296. 10.1016/j.ijcard.2008.10.048, 19118910.
27. Kuvin JT, Mammen A, Mooney P, Alsheikh-Ali AA, Karas RH. Assessment of peripheral vascular endothelial function in the ambulatory setting. Vasc Med (London, England) 2007, 12(1):13-16.
28. Bethel MA, Sourij H. Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice. Curr Cardiol Rep 2012, 14(1):59-69. 10.1007/s11886-011-0229-7, 22094711.
29. Lau KK, Wong YK, Chan YH, Yiu KH, Teo KC, Li LS, Ho SL, Chan KH, Siu CW, Tse HF. Prognostic implications of surrogate markers of atherosclerosis in low to intermediate risk patients with type 2 diabetes. Cardiovasc Diabetol 2012, 11:101. 10.1186/1475-2840-11-101, 3444371, 22900680.
30. Spence JD, Hackam DG. Treating arteries instead of risk factors: a paradigm change in management of atherosclerosis. Stroke 2010, 41(6):1193-1199. 10.1161/STROKEAHA.110.577973, 20413738.
31. Peters SA, Dogan S, Meijer R, Palmer MK, Grobbee DE, Crouse JR, O'Leary DH, Evans GW, Raichlen JS, Bots ML. The use of plaque score measurements to assess changes in atherosclerotic plaque burden induced by lipid-lowering therapy over time: the METEOR study. J Atheroscler Thromb 2011, 18(9):784-795. 10.5551/jat.8169, 21617330.
32. Al-Shali K, House AA, Hanley AJ, Khan HM, Harris SB, Mamakeesick M, Zinman B, Fenster A, Spence JD, Hegele RA. Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions. Atherosclerosis 2005, 178(2):319-325. 10.1016/j.atherosclerosis.2004.08.016, 15694940.
33. Prati P, Tosetto A, Casaroli M, Bignamini A, Canciani L, Bornstein N, Prati G, Touboul PJ. Carotid plaque morphology improves stroke risk prediction: usefulness of a new ultrasonographic score. Cerebrovasc Dis 2011, 31(3):300-304. 10.1159/000320852, 21212660.
34. van der Meer IM, Iglesias Del Sol A, Hak AE, Bots ML, Hofman A, Witteman JC. Risk factors for progression of atherosclerosis measured at multiple sites in the arterial tree: the rotterdam study. Stroke 2003, 34(10):2374-2379. 10.1161/01.STR.0000088643.07108.19, 12947155.
35. Herder M, Arntzen KA, Johnsen SH, Mathiesen EB. The metabolic syndrome and progression of carotid atherosclerosis over 13 years. Tromso Stud Cardiovasc Diabetol 2012, 11:77.